WO2012032103A1 - Mutant channelrhodopsin 2 - Google Patents
Mutant channelrhodopsin 2 Download PDFInfo
- Publication number
- WO2012032103A1 WO2012032103A1 PCT/EP2011/065510 EP2011065510W WO2012032103A1 WO 2012032103 A1 WO2012032103 A1 WO 2012032103A1 EP 2011065510 W EP2011065510 W EP 2011065510W WO 2012032103 A1 WO2012032103 A1 WO 2012032103A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- light
- cell
- cys
- ion channel
- seq
- Prior art date
Links
- 108010035848 Channelrhodopsins Proteins 0.000 title claims abstract description 24
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 22
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 22
- 239000013604 expression vector Substances 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 160
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 91
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 75
- 102000004310 Ion Channels Human genes 0.000 claims description 71
- 108090000862 Ion Channels Proteins 0.000 claims description 71
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 48
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 39
- 230000001965 increasing effect Effects 0.000 claims description 39
- 108091006146 Channels Proteins 0.000 claims description 37
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 239000011575 calcium Substances 0.000 claims description 32
- 206010034960 Photophobia Diseases 0.000 claims description 23
- 208000013469 light sensitivity Diseases 0.000 claims description 23
- 235000020945 retinal Nutrition 0.000 claims description 17
- 230000002207 retinal effect Effects 0.000 claims description 17
- 230000000638 stimulation Effects 0.000 claims description 17
- 210000004295 hippocampal neuron Anatomy 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000013537 high throughput screening Methods 0.000 claims description 13
- 150000003726 retinal derivatives Chemical class 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 238000001415 gene therapy Methods 0.000 claims description 7
- 238000003384 imaging method Methods 0.000 claims description 7
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 6
- 208000005400 Synovial Cyst Diseases 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- 238000002679 ablation Methods 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 4
- 201000004569 Blindness Diseases 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000004565 granule cell Anatomy 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 3
- 210000000449 purkinje cell Anatomy 0.000 claims description 3
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 claims description 3
- MIMKOTXYWWOEFT-UHFFFAOYSA-N 3,7-dimethyldeca-2,4,6,8-tetraenal Chemical compound CC=CC(C)=CC=CC(C)=CC=O MIMKOTXYWWOEFT-UHFFFAOYSA-N 0.000 claims description 2
- UDYGWSPUYSRWRN-UHFFFAOYSA-N 3,7-dimethylocta-2,4,6-trienal Chemical compound CC(C)=CC=CC(C)=CC=O UDYGWSPUYSRWRN-UHFFFAOYSA-N 0.000 claims description 2
- QPRQNCDEPWLQRO-UHFFFAOYSA-N 3R-hydroxy-all-trans-retinal Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CC(O)CC1(C)C QPRQNCDEPWLQRO-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- QPRQNCDEPWLQRO-DAWLFQHYSA-N all-trans-3-Hydroxyretinal Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(O)CC1(C)C QPRQNCDEPWLQRO-DAWLFQHYSA-N 0.000 claims description 2
- CYVVUYORRQQAQE-RMWYGNQTSA-N all-trans-4-hydroxyretinal Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C CYVVUYORRQQAQE-RMWYGNQTSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 210000001052 bipolar neuron Anatomy 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 210000003078 multipolar neuron Anatomy 0.000 claims description 2
- 210000001176 projection neuron Anatomy 0.000 claims description 2
- 210000001510 pseudounipolar neuron Anatomy 0.000 claims description 2
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 230000001976 improved effect Effects 0.000 abstract description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 90
- 239000012528 membrane Substances 0.000 description 36
- 210000002569 neuron Anatomy 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 210000003050 axon Anatomy 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- 230000028161 membrane depolarization Effects 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 210000000287 oocyte Anatomy 0.000 description 15
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 230000010221 calcium permeability Effects 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000036982 action potential Effects 0.000 description 11
- 210000001787 dendrite Anatomy 0.000 description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
- 230000009460 calcium influx Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- 108010062745 Chloride Channels Proteins 0.000 description 9
- 102000011045 Chloride Channels Human genes 0.000 description 9
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000005286 illumination Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000004257 Potassium Channel Human genes 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 108091008695 photoreceptors Proteins 0.000 description 7
- 108020001213 potassium channel Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 210000002763 pyramidal cell Anatomy 0.000 description 7
- 230000002336 repolarization Effects 0.000 description 7
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 7
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 6
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 6
- 241000269368 Xenopus laevis Species 0.000 description 6
- 238000001720 action spectrum Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007747 plating Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 210000005056 cell body Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000002999 depolarising effect Effects 0.000 description 5
- 238000010304 firing Methods 0.000 description 5
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229960004198 guanidine Drugs 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 108010082845 Bacteriorhodopsins Proteins 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 description 4
- 239000002262 Schiff base Substances 0.000 description 4
- 150000004753 Schiff bases Chemical class 0.000 description 4
- 241000269370 Xenopus <genus> Species 0.000 description 4
- 210000000411 amacrine cell Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- 108091005462 Cation channels Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005283 ground state Effects 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 2
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 2
- URNCTMHGJQSLOC-UHFFFAOYSA-N 4-[4-[(1z,3e)-4-[4-(dipentylamino)phenyl]buta-1,3-dienyl]pyridin-1-ium-1-yl]butane-1-sulfonate Chemical compound C1=CC(N(CCCCC)CCCCC)=CC=C1C=CC=CC1=CC=[N+](CCCCS([O-])(=O)=O)C=C1 URNCTMHGJQSLOC-UHFFFAOYSA-N 0.000 description 2
- QZXAEJGHNXJTSE-UHFFFAOYSA-N 7-(ethylamino)-4,6-dimethylchromen-2-one Chemical compound O1C(=O)C=C(C)C2=C1C=C(NCC)C(C)=C2 QZXAEJGHNXJTSE-UHFFFAOYSA-N 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000004330 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 238000013378 biophysical characterization Methods 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003473 flash photolysis reaction Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000017813 membrane repolarization Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000008587 neuronal excitability Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000004224 potassium gluconate Substances 0.000 description 2
- 229960003189 potassium gluconate Drugs 0.000 description 2
- 235000013926 potassium gluconate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000036390 resting membrane potential Effects 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- BTUZNIQVZBANAX-SWQYCTROSA-N (13Z,17Z,21Z,29Z)-48-(8-aminooctan-2-yl)-8,10,16,20,24,26,28,32,36,38,40,42,44,46-tetradecahydroxy-9,15,17,19,21,25,31,33,39,41,47-undecamethyl-23-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1-oxacyclooctatetraconta-13,17,21,29-tetraen-2-one Chemical compound CC1CCC(CC(C(C(C(C(CC(CC(C(C(OC(=O)CCCCCC(C(C(CC/C=C\C(C(/C(=C\C(C(/C(=C\C(C(C(C(CC(/C=C\C(C1O)C)O)O)C)O)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)/C)O)C)/C)O)C)O)C)O)C(C)CCCCCCN)C)O)O)O)C)O)C)O)O BTUZNIQVZBANAX-SWQYCTROSA-N 0.000 description 1
- NCYCYZXNIZJOKI-HWCYFHEPSA-N 13-cis-retinal Chemical compound O=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HWCYFHEPSA-N 0.000 description 1
- WWRGFLIMFQYXRS-UHFFFAOYSA-N 3,7,11-trimethyldodeca-2,4,6,8,10-pentaenal Chemical compound CC(C)=CC=CC(C)=CC=CC(C)=CC=O WWRGFLIMFQYXRS-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-MKOSUFFBSA-N 9-cis-retinal Chemical compound O=C/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-MKOSUFFBSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 description 1
- -1 Ca++-activated chloride Chemical class 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102220598266 Cancer/testis antigen family 45 member A10_C36A_mutation Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102220467332 Protein BEX4_L94A_mutation Human genes 0.000 description 1
- 102220465425 Protein arginine N-methyltransferase 1_L93A_mutation Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 101710150115 Sensory rhodopsin-2 Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000195614 Volvox carteri Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100001096 no neurotoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001743 on-bipolar cell Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 102220029346 rs34541442 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000873 signs of neurotoxicity Toxicity 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Definitions
- the invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.
- ChR2 channelrhodopsin-2
- WT wild-type ChR2
- WO 03/084994 and 5"7 Higher efficacy would enable depolarization of cell layers distant from the applied light source despite the low optical transmittance of, e.g., brain tissue.
- CatCh has a four-fold higher Ca ++ - permeability, a 70-fold higher light-sensitivity and faster response kinetics when expressed in hippocampal neurons compared to the WT ChR2.
- the enhanced light sensitivity and fast kinetics are shown to stem from the relatively high light-gated Ca ++ -influx, which elevates the inner membrane surface potential and activates Ca ++ -activated large conductance potassium (BK) channels.
- An increase in [Ca ++ ]i elevates the internal surface potential, facilitating activation of voltage-gated Na + -channels and indirectly increasing light- sensitivity.
- Repolarization following light-stimulation is markedly accelerated by Ca ++ - dependent B -channel activation.
- CatCh exemplifies a new principle by which light-gated channels can be engineered to increase the light sensitivity of neuronal stimulation. Its characteristics such as triggering precise and fast action potentials while requiring low light intensities for activation open the way for the use of light-gated channels in clinical applications.
- the invention relates to a light-inducible ion channel, wherein the light-inducible ion channel comprises an amino acid sequence which has at least 70% homology to the amino acid sequence shown in positions 1-309 of SEQ ID NO: 1 (CHOP -2), and which comprises a mutation at a position corresponding to LI 32 in SEQ ID NO: l.
- the invention also relates to a channelrhodopsin, comprising the light-inducible ion channel according to the first aspect and a retinal or retinal derivative.
- the invention provides a nucleic acid construct, comprising a nucleotide sequence coding for the light-inducible ion channel according to the first aspect.
- the invention provides an expression vector, comprising a nucleotide sequence coding for the light-inducible ion channel according to the first aspect or the nucleic acid construct according to the third aspect.
- a cell is provided, comprising the channelrhodopsin according to the second aspect, the nucleic acid constmct according to the third aspect, or the expression vector according to the fourth aspect.
- the invention pertains to the use of the light inducible ion channel according to the first aspect, the channelrhodopsin of the second aspect, the nucleic acid construct or the expression vector according to the invention, and the cell according to the invention as a medicament.
- a use of the expression vector according to the invention in gene therapy is contemplated.
- the use of the light-inducible ion channel, channelrhodopsin, nucleic acid constmct, expression vector, or cell according to the invention in the treatment of blindness or reduced sight is contemplated.
- the invention provides the use of the light-inducible ion-channel according to the first aspect, additionally having threonine, serine, or alanine at a position corresponding to position 128 of SEQ ID NO: 1; and/or alanine at a position corresponding to position 156 of SEQ ID NO: 1, in the ablation of cancer cells.
- the invention relates to the use of a light-inducible ion channel according to the first aspect, or a channelrhodopsin according to the second aspect, or a cell according to the invention in a high-throughput screening.
- the invention relates to a light-inducible ion channel, wherein the light- inducible ion channel comprises an amino acid sequence which has at least 70% identity to the amino acid sequence shown in positions 1-309 of SEQ ID NO: 1 (CHOP-2), more preferably to the amino acid sequence shown in positions 1-315 of SEQ ID NO: 1, or even to the amino acid sequence shown in positions 1- 737 of SEQ ID NO: 1, and which comprises a mutation at a position corresponding to LI 32 in SEQ ID NO: 1.
- the light- inducible ion channel comprises an amino acid sequence which has at least 70% identity to the amino acid sequence shown in positions 1-309 of SEQ ID NO: 1 (CHOP-2), more preferably to the amino acid sequence shown in positions 1-315 of SEQ ID NO: 1, or even to the amino acid sequence shown in positions 1- 737 of SEQ ID NO: 1, and which comprises a mutation at a position corresponding to LI 32 in SEQ ID NO: 1.
- Wild-type CHOP2 has the following amino acid sequence:
- the light inducible ion channel of the invention is a membrane protein with at least 5 transmembrane helices, which is capable of binding a light-sensitive polyene.
- Transmembrane proteins with 6 or 7 transmembrane helices are preferable.
- Transmembrane proteins with more than 7 helices, for example 8, 9 or 10 transmembrane helices, are however also covered by the invention.
- transmembrane proteins which in addition to the transmembrane part include C- and/or N- terminal sequences, where the C-terminal sequences can extend into the inside of the lumen enclosed by the membrane, for example the cytoplasm of a cell or the inside of a liposome, or can also be arranged on the membrane outer surface.
- C-terminal sequences can extend into the inside of the lumen enclosed by the membrane, for example the cytoplasm of a cell or the inside of a liposome, or can also be arranged on the membrane outer surface.
- the optionally present N-terminal sequences which can likewise be arranged both within the lumen and also on the outer surface of the membrane.
- the length of the C- and/or N- terminal sequences is in principle subject to no restriction; however, light-inducible ion channels with C-terminal sequences not embedded in the membrane, with 1 to 1000 amino acids, preferably 1 to 500, especially preferably 5 to 50 amino acids, are preferred.
- the N-terminal located sequences not embedded in the membrane preferably comprise 1 to 500 amino acids, especially preferably 5 to 50 amino acids.
- the concept of the transmembrane helix is well known to the skilled person. These are generally a-helical protein structures, which as a rule comprise 20 to 25 amino acids.
- transmembrane segments can also be shorter or longer.
- transmembrane segments in artificial membranes can comprise up to 30 amino acids, but on the other hand also only a few amino acids, for example 12 to 16.
- the light-inducible ion channel comprises an amino acid sequence which has at least 70% identity, preferably at least 75% identity, more preferably at least 80% identity, even more preferably at least 85% identity, such as at least 90% identity, and most preferably at least 95% identity to the amino acid sequence shown in positions 1-309 of SEQ ID NO: 1.
- the light-inducible ion channel comprises an amino acid sequence which has at least 70% identity, preferably at least 75% identity, more preferably at least 80% identity, even more preferably at least 85% identity, such as at least 90% identity, and most preferably at least 95% identity to the amino acid sequence shown in positions 1-315 of SEQ ID NO: 1.
- an amino acid sequence has "at least x % identity" with another amino acid sequence or SEQ ID NO: 1 above, when the sequence identity between those to aligned sequences is at least x %.
- Such an alignment can be performed using for example publicly available computer homology programs such as the "BLAST" program provided at the NCBI homepage at http://www.ncbi.nlm.nih.gov/blast blast.cgi, using the default settings provided therein. Further methods of calculating sequence identity percentages of sets of nucleic acid sequences are known in the art.
- Examples for such light-inducible ion channels comprising an amino acid sequence which has at least 70% identity to the amino acid sequence shown in positions 1-309 or 1-315 of SEQ ID NO: 1 is CHOPl from C. reinhardtii (gi: 15811379), CHOP2 (gi: 167650748) and CHOPl (gi: 167650744) from Volvox carteri, or any other ortholog or allelic variant of CHOP2 or CHOPl.
- the light-inducible ion channel comprises, preferably consists of the amino acid sequence shown in positions 1-309 of SEQ ID NO: 1 (CHOP-2), except for a mutation at position LI 32.
- the light-inducible ion channel comprises, preferably consists of the amino acid sequence shown in positions 1-315 of SEQ ID NO: 1 (CHOP-2), except for a mutation at position LI 32.
- the mutation at position LI 32, or at the position corresponding to LI 32 in SEQ ID NO: 1 may be a substitution, addition and/or a deletion.
- the mutation is a substitution, more preferably selected from L132C, L132S, L132E, L132D, and L132T, most preferably wherein the substitution is L132C.
- the substitutions L132S, L132E, L132D, and L132T will exhibit similar properties, since all these substitutions will increase the polarity of the channel.
- the light-inducible ion channel comprises further (semi-)conservative substitutions.
- Conservative substitutions are those that take place within a family of amino acids that are related in their side chains and chemical properties. Examples of such families are amino acids with basic side chains, with acidic side chains, with non-polar aliphatic side chains, with non-polar aromatic side chains, with uncharged polar side chains, with small side chains, with large side chains etc.
- Typical semi- conservative and conservative substitutions are:
- the light-inducible ion channel comprises the consensus motif L(I)DxxxKxxW(F,Y). Amino acids given in brackets can in each case replace the preceding amino acid.
- This consensus sequence is the motif surrounding the retinal- binding amino acid lysine.
- CatCh spikes can be generated even by excitation far from its spectral maximum of 474 nm, e.g. with green light (532 nm - see Fig. 4d).
- Green light 532 nm - see Fig. 4d.
- Working at the outer flanks of the action spectrum is feasible due to its reduced light-requirements and facilitates tissue penetration.
- the light-sensitivity of the mutant light-inducible ion channel of the invention is preferably increased by more than 5 times, preferably by more than 10 times, more preferably by more than 20 times, such as 30 times, even more preferably by more than 40 times, such as 50 times, and most preferably by more than 60 times, or even by more than 70 times, as compared to WT CHOP-2 in hippocampal neurons.
- the mutant light- inducible ion channel of the invention exhibits a stimulation frequency which is increased at least 1.5-fold, more preferably 2-fold, or even more preferably 2.5 fold, compared to WT CHOP-2 as determined by whole-cell electrophysiological recordings in hippocampal neurons.
- WT-Chop2 exhibits a stimulation frequency in hippocampal neurons of about 10 Hz up to about 20 Hz, wherein at 20 Hz signalling is already inaccurate.
- the intrinsic spike frequency is also dependent on the cell type. For example, auditory cells have an intrinsic spike frequency of up to 500 Hz.
- the experiments have been conducted in vitro, i.e. at ambient temperature. However, the skilled person will expect that the stimulation frequency will be even higher in warm-blooded animals, such as mammals, since the kinetics are also temperature-dependent.
- the mutant light-inducible ion channel of the invention may also exhibit a stimulation frequency which is increased at least 5-fold, preferably at least 10-fold, such as at least 20-fold, or at least 30-fold, or more preferably at least 40-fold, at least 50-fold, such as at least 60-fold, or at least 70-fold, even more preferably at least 80-fold, at least 90-fold, or at least 100-fold, most preferably at least 125-fold, such as at least 150-fold, or at least 175-fold, and even most preferably at least 200-fold, compared to WT CHOP-2 as determined by whole-cell electrophysiological recordings. Hippocampal neuron culture and electrophysiological recordings from hippocampal neurons is exemplified in the examples below.
- Hippocampi are isolated from postnatal PI Sprague-Dawley rats (Jackson Laboratory) and treated with papain (20 U ml-1) for 20 min at 37°C.
- the hippocampi are washed with DMEM (Invitrogen/Gibco, high glucose) supplemented with 10% fetal bovine serum and triturated in a small volume of this solution.
- DMEM Invitrogen/Gibco, high glucose
- fetal bovine serum fetal bovine serum
- ⁇ 75,000 cells are plated on poly-D-lysine / laminin coated glass cover slips in 24-well plates. After 3 hours the plating medium is replaced by culture medium (Neurobasal A containing 2% B-27 supplement, 2 mM Glutamax-I and 100 U/ml penicillin and 100 ⁇ streptomycin).
- Mutant ChR2(L132C)-YFP and ChR2 (WT)-YFP are transfected 5-10 days after plating using the lipofectamine 2000 reagent (Invitrogen).
- 2-5 ⁇ 109 GC/ml of vims (AAV2/7-CAG-ChR2(L132C)-2A-EGFP-WPRE-bGH) may be added to each well 4-9 days after plating.
- Representative construction of the Adeno-associated viral vector construct is described in detail in the examples below. Expression becomes visible 5 days post-transduction. No all-trans retinal is added to the culture medium or recording medium for any of the experiments.
- patch pipettes with resistances of 5-10 ⁇ are filled with 129 mM potassium gluconate, 10 mM HEPES, 10 mM KC1, 4 mM MgATP and 0.3 mM Na 3 GTP, titrated to pH 7.2.
- Tyrode's solution is employed as the extracellular solution (125 mM NaCl, 2 mM KC1, 2 mM CaCl 2 , 1 mM MgCl 2 , 30 mM glucose and 25 mM HEPES, titrated to pH 7.4).
- the nominally Ca ++ -free extracellular solution contains this same solution except that it has 0 mM Ca ⁇ and 3 mM Mg ++ .
- Recordings are conducted in the presence of the excitatory synaptic transmission blockers, l,2,3,4-tetrahydiO-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX, 10 uM, Sigma) and D(-)-2-Amino-5-phosphonopentanoic acid (AP-5, 50 ⁇ , Sigma).
- NBQX excitatory synaptic transmission blockers
- AP-5 D(-)-2-Amino-5-phosphonopentanoic acid
- Electrophysiological signals are amplified using an Axopatch 200A amplifier (Axon Instruments, Union City, CA), filtered at 10 kHz, digitized with an Axon Digidata 1600 (50 Hz) and acquired and analyzed using pClamp9 software (Axon Instruments).
- Specific light intensities are intensities at the end of a 400 ⁇ diameter quartz optic fiber (STE-F100/400- Y-VIS/NIR; Laser 2000, Wessling, Germany) at a distance of -500 ⁇ from the cell.
- the calcium conductivity of the mutant light- inducible ion channel of the invention is increased at least two-fold, preferably at least three-fold, more preferably at least four-fold compared to WT CHOP-2, as determined by Fura-2-imaging on HEK293 cells.
- Fura-2 AM (5 raM; Invitrogen) is loaded at room temperature for 30 min to 1 hour.
- the cells are recovered in a 140 mM NaCl solution without Ca* " (140 mM NaCl, 7 mM EGTA, 2 mM MgCl 2 and 10 mM HEPES).
- Yellow fluorescent protein is excited by a 500 ms exposure to light using a 460/40 nm filter (Visitron Systems, Puchheim, Germany) to estimate each cell's expression level from its YFP-fluorescence.
- the solution is then replaced by an extracellular Ca ++ -solution that consists of 90 mM CaCl 2 , 7 mM EGTA, 2 mM MgCl 2 and 10 mM HEPES.
- the light- gated channels are stimulated for 10 s with blue light (460/40 nm).
- Fura-2 is excited with 340 nm (340/20) and 380 nm (380/20) and the emitted light (540/80 nm) detected with a CCD camera (all filters from Visitron Systems, Puchheim, Germany).
- the mutant light-inducible ion channel may additionally comprise further mutations, preferably substitutions.
- the light- inducible ion channel may additionally comprise at least one of the following amino acid residues: aspartic acid at a position corresponding to position 253 of SEQ ID NO: 1; lysine at a position corresponding to position 257 of SEQ ID NO: 1 ; tryptophan at a position corresponding to position 260 of SEQ ID NO: 1; glutamic acid at a position corresponding to position 123 of SEQ ID NO: 1; histidine or arginine, preferably arginine, at a position corresponding to position 134 of SEQ ID NO: 1; threonine, serine, or alanine at a position corresponding to position 128 of SEQ ID NO: 1; and/or alanine at a position corresponding to position 156 of SEQ ID NO: 1.
- the mutant light-inducible ion channel may comprise one of the mutant light-inducible i
- Cys 132 may also be substituted by either Ser 132, Glu 132, Asp 132, or Thr 132.
- the retinal or retinal derivative necessary for the functioning of the light- inducible ion channel is produced by the cell to be transfected with said ion channel.
- the retinal may be all-trans retinal, 11-cis-retinal, 13-cis- retinal, or 9-cis-retinal.
- the mutant light-inducible ion channel of the invention may be incorporated into vesicles, liposomes or other artificial cell membranes.
- the invention provides a channelrhodopsin, comprising the light-inducible ion channel according to the first aspect and a retinal or retinal derivative.
- the retinal derivative is selected from the group consisting of 3,4-dehydroretinal, 13-ethylretinal, 9-dm-retinal, 3- hydroxyretinal, 4- hydroxyretinal, naphthylretinal; 3,7,11 -trimethyl-dodeca-2,4,6,8, 10- pentaenal; 3,7- dimethyl-deca-2,4,6,8-tetraenal; 3 ,7-dimethyl-octa-2,4,6-trienal; and 6-7 rotation-blocked retinals, 8-9 rotation-blocked retinals, and 10-11 rotation-blocked retinals.
- the preferred embodiments of the first aspect correspond to the preferred embodiments of the second aspect.
- the invention also relates to a nucleic acid construct, comprising a nucleotide sequence coding for the light-inducible ion channel according to the first aspect.
- the coding DNA can also be suitably modified, for example by adding suitable regulatory sequences and/or targeting sequences and/or by matching of the coding DNA sequence to the preferred codon usage of the chosen host.
- the targeting sequence may encode a C-terminal extension targeting the light-inducible ion channel to a particular site or compartment within the cell, such as to the synapse or to a post-synaptic site, to the axon-hillock, or the endoplasmic reticulum.
- the nucleic acid may be combined with further elements, e.g., a promoter and a transcription start and stop signal and a translation start and stop signal and a polyadenylation signal in order to provide for expression of the sequence of the protein of the invention.
- the promoter can be inducible or constitutive, general or cell specific promoter.
- An example of a cell-specific promoter is the mGlu6-promotor specific for bipolar cells. Selection of promoters, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.
- the invention provides an expression vector, comprising a nucleotide sequence coding for the light-inducible ion channel according to the first aspect or the nucleic acid construct according to the third aspect.
- the vector is suitable for gene therapy, in particular wherein the vector is suitable for vims- mediated gene transfer.
- suitable for virus-mediated gene transfer means herein that said vector can be packed in a virus and thus be delivered to the site or the cells of interest.
- viruses suitable for gene therapy are retroviruses, adenoviruses, adeno-associated viruses, lentiviruses, pox viruses, alphaviruses, rabies virus, semliki forest virus and herpes viruses.
- the resulting nucleic acid sequence may be introduced into cells e.g. using a virus as a carrier or by transfection including e.g. by chemical transfectants (such as Lipofectamine, Fugene, etc.), electroporation, calcium phosphate co-precipitation and direct diffusion of DNA.
- a method for transfecting a cell is detailed in the examples and may be adapted to the respective recipient cell.
- Transfection with DNA yields stable cells or cell lines, if the transfected DNA is integrated into the genome, or unstable (transient) cells or cell lines, wherein the transfected DNA exists in an extrachromosomal form.
- stable cell lines can be obtained by using episomal replicating plasmids, which means that the inheritance of the extrachromosomal plasmid is controlled by control elements that are integrated into the cell genome.
- the selection of a suitable vector or plasmid depends on the intended host cell.
- the invention relates to a cell comprising the channelrhodopsin according to the second aspect, the nucleic acid construct according to the third aspect or the expression vector according to the fourth aspect.
- one application of the mutant light-inducible ion channel according to the present invention is the treatment of blind subjects such as humans or animals.
- blind subjects such as humans or animals.
- the deliberate expression of light-controlled ion channels according to the invention in these ganglion cells, amacrine cells or bipolar cells would be a very much more elegant solution and enable greater three-dimensional visual resolution.
- the incorporation of the mutant light-inducible ion channel into the membrane of cells which do not express the corresponding channels in nature can for example be simply effected in that, using known procedures of recombinant DNA technology, the DNA coding for this ion channel is firstly incorporated into a suitable expression vector, e.g. a plasmid, a cosmid or a vims, the target cells are then transformed with this, and the protein is expressed in this host. Next, the cells are treated in a suitable manner, e.g. with retinal, in order to enable the linkage of a Schiffs base between protein and retinal.
- a suitable expression vector e.g. a plasmid, a cosmid or a vims
- this occurs in various yeasts such as Saccharomyces cerevisiae, Schizosaccharo-myces pombe or Pichia pastoris as already successfully performed for rhodopsins such as bacteriorhodopsin and/or bovine rhodopsin.
- the expression can also be effected in certain mammalian cell systems or insect cell systems.
- the cell is a mammalian cell or an insect cell.
- the expression is effected either with episomal vectors as transient expression, preferably in melanoma cells (e.g., the BLM cell line), COS cells (generated by infection of "African green monkey kidney CV1" cells) or HEK cells ("human embryonic kidney cells", e.g. HEK293 cells), or BH -cells ("baby hamster kidney cells”), or in the form of stable expression (by integration into the genome) in CHO cells ("Chinese hamster ovary cells"), myeloma cells or MDCK cells ("Madine-Darby canine kidney cells”) or in Sf9 insect cells infected with baculoviruses.
- the mammalian cell is a COS cell; a BHK cell; a HEK293 cell; a CHO cell; a myeloma cell; or a MDCK cell.
- the mammalian cell is a photoreceptor cell; a retinal rod cell; a retinal cone cell; a retinal ganglion cell; a bipolar neuron; a ganglion cell; a pseudounipolar neuron; a multipolar neuron; a pyramidal neuron, a Purkinje cell; or a granule cell.
- a neuron is an electrically excitable cell that processes and transmits information by electrical and chemical signalling, wherein chemical signaling occurs via synapses, specialized connections with other cells.
- a number of specialized types of neurons exist such as sensory neurons responding to touch, sound, light and numerous other stimuli affecting cells of the sensory organs, motor neurons receiving signals from the brain and spinal cord and causing muscle contractions and affecting glands, and intemeurons connecting neurons to other neurons within the same region of the brain or spinal cord.
- a neuron possesses a soma, dendrites, and an axon. Dendrites are filaments that arise from the cell body, often extending for hundreds of microns and branching multiple times.
- An axon is a special cellular filament that arises from the cell body at a site called the axon hillock.
- the cell body of a neuron frequently gives rise to multiple dendrites, but never to more than one axon, although the axon may branch hundreds of times before it terminates.
- signals are sent from the axon of one neuron to a dendrite of another.
- neurons that lack dendrites neurons that have no axon, synapses that connect an axon to another axon or a dendrite to another dendrite, etc.
- Most neurons can further be anatomically characterized as unipolar or pseudounipolar (dendrite and axon emerge from same process), bipolar (axon and single dendrite on opposite ends of the soma), multipolar (having more than two dendrites and may be further classified as (i) Golgi I neurons with long-projecting axonal processes, such as pyramidal cells, Purkinje cells, and anterior horn cells, and (ii) Golgi II: neurons whose axonal process projects locally, e.g., granule cells.
- a photoreceptor cell is a specialized neuron found in the retina that is capable of phototransduction.
- the two classic photoreceptors are rods and cones, each contributing information used by the visual system.
- a retinal ganglion cell is a type of neuron located near the inner surface of the retina of the eye. These cells have dendrites and long axons projecting to the pro tectum (midbrain), the suprachiasmatic nucleus in the hypothalamus, and the lateral geniculate (thalamus). A small percentage contribute little or nothing to vision, but are themselves photosensitive. Their axons form the retinohypothalamic tract and contribute to circadian rhythms and pupillary light reflex, the resizing of the pupil.
- bipolar cells receive visual information from photoreceptors via two intermediate neuron types: bipolar cells and amacrine cells.
- Amacrine cells are intemeurons in the retina, and responsible for 70% of input to retinal ganglion cells.
- Bipolar cells which are responsible for the other 30% of input to retinal ganglia, are regulated by amacrine cells.
- the bipolar cell exists between photoreceptors (rod cells and cone cells) and ganglion cells. They act, directly or indirectly, to transmit signals from the photoreceptors to the ganglion cells.
- the cell may be isolated (and genetically modified), maintained and cultured at an appropriate temperature and gas mixture (typically, 37°C, 5% C02), optionally in a cell incubator as known to the skilled person and as exemplified for certain cell lines or cell types in the examples.
- Culture conditions may vary for each cell type, and variation of conditions for a particular cell type can result in different phenotypes. Aside from temperature and gas mixture, the most commonly varied factor in cell culture systems is the growth medium.
- Recipes for growth media can vary in pH, glucose concentration, growth factor and the presence of other nutrient components among others. Growth media are either commercially available, or can be prepared according to compositions, which are obtainable from the American Tissue Culture Collection (ATCC). Growth factors used for supplement media are often derived from animal blood such as calf serum. Additionally, antibiotics may be added to the growth media.
- ATCC American Tissue Culture Collection
- CatCh Since Ca ⁇ is an important intracellular regulator, CatCh opens the doors to optical intervention into the fine-tuned Ca ++ homeostasis of the cell, modulating its state and activity.
- CatCh may be used to optically control Ca ++ -dependent exocytosis as an alternative to caged Ca ⁇ 26 (e.g. transmitter release at the synapse), to optically activate downstream intracellular processes via calcium-activated kinases and phosphatases or to induce apoptosis by targeting CatCh to intracellular compartments such as the Golgi apparatus or endoplasmatic reticulum.
- a further aspect of the invention is the use of the light-inducible ion channel according to the first aspect or channelrhodopsin according to the second aspect, or the nucleic acid construct according to the third aspect, or the cell according to the invention as a medicament.
- the expression vector of the invention may be used in gene therapy.
- the light-inducible ion channel according to the first aspect, channelrhodopsin according to the second aspect, nucleic acid construct according to the third aspect, or the cell according to the invention may be used in the treatment of blindness or reduced sight.
- a use of the light-inducible ion channel in the reestablishing of hearing or the treatment of deafness is also contemplated.
- the mutant light-inducible ion channel according to the first aspect may comprise additional substitutions (so called SFO's, or slow mutants, see Table 1), which lead to a permanent light-induced calcium-influx, which in turn leads to cell death.
- SFO's additional substitutions
- a use of the light-inducible ion-channel according to the invention additionally having threonine, serine, or alanine at a position corresponding to position 128 of SEQ ID NO: 1; and/or alanine at a position corresponding to position 156 of SEQ ID NO: 1 in the ablation of cancer cells is contemplated.
- the expression vector according to the invention could be targeted by virus-mediated gene transfer via a cancer cell surface marker to cancer cells.
- retroviruses preferably integrate into fast dividing cells, such as cancer cells.
- the light-inducible ion channel according to the present invention is predominantly expressed and incorporated into the cell membrane of cancer cells. Upon stimulation by light, these ion channels will open and induce a permanent calcium-influx, thereby leading to the death of the cancer cell.
- the cancer is a melanoma cancer.
- the invention pertains to a use of a light-inducible ion channel according to the first aspect, or a channelrhodopsin according to the second aspect, or a cell according to the invention in a high-throughput screening.
- a high-throughput screening is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. HTS allows a researcher to effectively conduct millions of biochemical, genetic or pharmacological tests in a short period of time, often through a combination of modern robotics, data processing and control software, liquid handling devices, and sensitive detectors.
- active agents which modulate a particular biomolecular pathway particularly a substance modifying an ion channel, such as the light-inducible ion channel according to the invention, a Ca ++ -inducible potassium channel, or a BK channel.
- a substance modifying an ion channel such as the light-inducible ion channel according to the invention, a Ca ++ -inducible potassium channel, or a BK channel.
- active agents which modulate a particular biomolecular pathway particularly a substance modifying an ion channel, such as the light-inducible ion channel according to the invention, a Ca ++ -inducible potassium channel, or a BK channel.
- a substance modifying an ion channel such as the light-inducible ion channel according to the invention, a Ca ++ -inducible potassium channel, or a BK channel.
- the light-inducible channel will open and the intracellular Ca ++ concentration will increase, thereby activating the potassium channel.
- RH 421 N-(4-Sulfobutyl)-4-(4-(4- (dipentylamino)phenyl)butadienyl)pyridinium, inner salt.
- Such a HTS may thus comprise the following steps: (i) contacting a cell expressing a Ca ++ -inducible (potassium) channel and the light-inducible ion channel according to the invention with a candidate agent directed against the Ca ++ -inducible channel, (ii) applying a light stimulus in order to induce the light-inducible channel, (iii) determining the alteration of the membrane potential (mixed signal), and (iv) comparing the signal determined in step (iii) with the signal determined in a cell only expressing the light-inducible ion channel according to the invention subjected to step (ii) (single signal).
- a reduction in the change of the membrane potential would be indicative of a promising modulator of the Ca ++ -inducible (potassium) channel.
- Such an approach is supposed to yield a signal-to-noise ratio of approximately 5:1, which is quite improved compared to direct measurements conducted on a cell only expressing the Ca ++ -inducible channel. Due to the improved signal-to-noise ratio, said method, in particular by using the light-inducible ion channel, may be particularly suitable for HTS.
- HTS uses an approach to collect a large amount of experimental data on the effect of a multitude of substances on a particular target in a relatively short time.
- a screen in this context, is the larger experiment, with a single goal (usually testing a scientific hypothesis), to which all this data may subsequently be applied.
- HTS cells according to the invention may be seed in a tissue plate, such as a multi well plate, e.g. a 96-well plate. Then the cell in the plate is contacted with the test substance for a time sufficient to interact with the targeted ion channel. The test substance may be different from well to well across the plate.
- measurements are taken across all the plate's wells, either manually or by a machine and optionally compared to measurements of a cell which has not been contacted with the test substance.
- Manual measurements may be necessary when the researcher is using patch-clamp, looking for effects not yet implemented in automated routines.
- a specialized automated analysis machine can run a number of experiments on the wells (such as analysing light of a particular frequency or a high-throughput patch-clamp measurement). In this case, the machine outputs the result of each experiment e.g. as a grid of numeric values, with each number mapping to the value obtained from a single well.
- the researcher can perform follow up assays within the same screen by using substances similar to those identified as active (i.e. modifying an intracellular cyclic nucleotide level) into new assay plates, and then re-running the experiment to collect further data, optimize the structure of the chemical agent to improve the effect of the agent on the cell.
- Automation is an important element in HTS's usefulness.
- a specialized robot is often responsible for much of the process over the lifetime of a single assay plate, from creation through final analysis.
- An HTS robot can usually prepare and analyze many plates simultaneously, further speeding the data-collection process.
- Examples for apparatuses suitable for HTS in accordance with the present invention comprise a Fluorometric Imaging Plate Reader (FLIPRTM; Molecular Devices), FLEXstationTM (Molecular Devices), Voltage Ion Probe Reader (VIPR, Aurora Biosciences), Attofluor® Ratio Vision® (ATTO).
- FLIPRTM Fluorometric Imaging Plate Reader
- FLEXstationTM Molecular Devices
- VPR Voltage Ion Probe Reader
- TOO Attofluor® Ratio Vision®
- FIG. 1 Homology model of ChR2 based on the Sensory Rhodopsin 2 structure (PDB code 1H2S).
- the target region for the cysteine scanning (R115 to T139) is located in the transmembrane helix 3 (TM3) and is highlighted in red.
- the inset shows the presumable location of the mutated L132C, the hydrogen-bonded CI 28 and D156, connecting TM3 and TM4 as indicated by the dotted line, and the homologue residues for the proton donor (HI 34) and proton acceptor (El 23), respectively.
- the chromophore is formed by all-trans retinal (ATR) and K257 covalently linked by a Schiff-base.
- the cavity formed by the removal of the leucins's methyl groups is depicted as spheres and overlaid on the mutated sulfhydryl group of the cysteine residue (yellow ball).
- the figure was prepared with VMD
- the figure depicts the spectral changes after 450 nm excitation with the characteristic wavelengths for the deprotonated Schiff-base, P390 (381 nm, top panel), for P520, dominant in the open state (541 nm, second panel), and the ground state (440 nm, third panel).
- the first red-shifted intermediate, presumably P500, is not resolved and only detected as offset.
- the transitions in the photocycle resemble those observed in the WT.
- the mutation causes no gross change in the functional states.
- the open state is determined mainly by the P520 intermediate.
- the main difference is found in the extent of the P390 amplitude compared to P520 that is lower than in the WT. Therefore, the L132C mutation does not affect the light reaction at the chromophore site. Note that the spectroscopic kinetics data of the photocycle was not altered in the presence of 50 mM Ca ++ .
- FIG. 7 Surface potential changes induced by Ca ⁇ . It is known, that the voltage drop across the membrane depends on the applied potential difference ( ⁇ ') and is modified by the surface potential ( ⁇ 0 ). In general ⁇ 0 depends on the negative surface charge density, which can be modified by screening with counterions. Therefore the activation of the voltage-gated sodium channels (and other voltage-sensitive channels) can be influenced by the change of the surface charge either on the external or internal side of the membrane . In our case, the Ca ++ conducted through CatCh neutralizes the negative surface charges on the inner membrane face of the neuron. By this a depolarizing effect on the membrane potential is induced, leading to the induction of action potentials at lower light intensities.
- the L132C (CatCh) mutation displays significant alterations in the amplitude and shape of the current traces.
- C-terminally truncated ChR2(L132C)-YFP (vector: pcDNA3(-)-chop2-309-(L132C)-EYFP) was transfected in HEK293 cells and kept under G418 selection at all times (0.6 mg/ml; PAA Germany, Colbe, Germany).
- the C-terminally truncated ChR2-YFP (vector: pcDNA4TO-chop2- 309-EYFP) was stably transfected into HEK293-Trex cells (Invitrogen), cultured and induced as described .
- the peak to stationary relations were detennined from HEK293 cells transiently transfected (Effectene, QIAGEN) with human-codon-optimized pcDNA3.1(-)-ChR2-YFP constructs (WT, H134R or L132C) 24 hours prior to measurements. Electrophysiological recordings on HEK293 cells.
- external 140 mM NaCl was exchanged by 140 mM KC1, 90 mM CaCl 2 or 90 mM MgCl 2 , respectively.
- Proton permeabilities were determined from the reversal potential shift of the current-voltage-relationship when the pH was reduced from 9 to 7.4 (or 6). Permeability ratios were calculated according to the Goldman- Hodgkin-Katz (GHK) equation, including terms for Na + , K + , H + and Ca ++ .
- GLK Goldman- Hodgkin-Katz
- the pipette solution contained 1 mM Guanidine-HCl, 199 mM NMG-C1 (N-Methylglucamine), 10 mM EGTA, 2 mM MgCl 2 , and 20 mM Hepes (pH 7.4), the bath solution contained 200 mM guanidine-HCl, 2 mM MgCl 2 , 2 mM CaCl 2 , and 20 mM Hepes (pH 7.4).
- Xenopus laevis oocyte preparation and molecular biology A C-tenninally-trancated ChR2 variant (residues 1-315) without extracellularly exposed cysteine residues (containing mutations C34A and C36A) were subcloned into the vector pTLN 27 . Single cysteine mutations were introduced by QuickChange Site-Directed Mutagenesis (Stratagene) and verified by sequencing. The mRNA was prepared using the SP6 mMessage mMachine kit (Ambion, Austin, TX). 50 nl cRNA, which included 30 ng of WT ChR2/CatCh mRNA were injected into each Xenopus oocyte.
- Oocytes were obtained by collagenase treatment after partial ovarectomy. After cRNA injection, oocytes were incubated in all -trans retinal (1 ⁇ , from a 1 mM stock in ethanol) and were kept in ORI buffer (90 mM NaCl, 2 mM KCl, 2 mM CaCl 2 and 5 mM Mops, pH 7.4) containing 1 mg ml gentamycin at 18° C for two to four days. Two-electrode-voltage clamp on Xenopus laevis oocytes.
- ORI buffer 90 mM NaCl, 2 mM KCl, 2 mM CaCl 2 and 5 mM Mops, pH 7.4
- Photocurrents were activated with a 75-W xenon arc lamp and a 450 ⁇ 25 nm band filter, the light of which was coupled into a 1-mm-light-guide with an output of ⁇ 10 18 photons s "1 cm “2 .
- Action spectra were recorded using narrow bandwidth filters (398-645 nm; ⁇ 10 nm ; K-series Balzer) in combination with neutral density filters to achieve a fiber output of ⁇ 1.4 x 10 17 photons s "1 cm “2 for each wavelength.
- Ca ++ in the ORI solution was replaced by Ba ++ to suppress CaCC currents. Current amplitudes at each wavelength were normalized to represent equal photon exposure.
- Fura-2 calcium imaging on CatCh-expressing HEK293 cells and compared the measured 340/380 ratios to the ratios measured in WT ChR2-expressing cells.
- Fura-2-imaging on HEK293 cells Fura-2 AM (5 mM; Invitrogen) was loaded at room temperature for 30 min to 1 hour. After loading the cells were recovered in a 140 mM NaCl solution without Ca ++ (140 mM NaCl, 7 mM EGTA, 2 mM MgCl 2 and 10 mM HEPES). Yellow fluorescent protein was excited by a 500 ms exposure to light using a 460/40 nm filter (Visitron Systems, Puchheim, Germany) to estimate each cell's expression level from its YFP-fluorescence.
- the solution was then replaced by an extracellular Ca ++ -solution that consisted of 90 mM CaCl 2 , 7 mM EGTA, 2 mM MgCl 2 and 10 mM HEPES. After 15 min in the dark the light-gated channels were stimulated for 10 s with blue light (460/40 nm). Fura-2 was excited with 340 nm (340/20) and 380 nm (380/20) and the emitted light (540/80 nm) detected with a CCD camera (all filters from Visitron Systems, Puchheim, Germany).
- the construct was expressed in cultured hippocampal pyramidal cells.
- Hippocampal neuron culture Hippocampi were isolated from postnatal PI Sprague- Dawley rats (Jackson Laboratory) and treated with papain (20 U ml "1 ) for 20 min at 37°C. The hippocampi were washed with DMEM (Invitrogen/Gibco, high glucose) supplemented with 10% fetal bovine serum and triturated in a small volume of this solution. ⁇ 75,000 cells were plated on poly-D-lysine / laminin coated glass cover slips in 24-well plates.
- DMEM Invitrogen/Gibco, high glucose
- ChR2(L132C)-YFP and ChR2-YFP were transfected 5-10 days after plating using the lipofectamine 2000 reagent (Invitrogen).
- 2-5 ⁇ 10 9 GC/ml of vims AAV2/7-CAG-ChR2(L132C)-2A-EGFP-WPRE-bGH was added to each well 4-9 days after plating. Expression became visible 5 days post-transduction. No neurotoxicity was observed for the lifetime of the culture ( ⁇ 5 weeks). No all-trans retinal was added to the culture medium or recording medium for any of the experiments described here.
- the cytomegalovims early enhancer / chicken ⁇ -actin (CAG) promoter was PCR-amplified and inserted into pAAV2-Rho-EGFP (kind gift from Alberto Auricchio 28 ) to obtain pAAV2-CAG-EGFP.
- the pAAV2-CAG-EGFP viral expression plasmid contained additionally a woodchuck posttranscriptional regulatory element (WPRE) and a bovine growth hormone (BGH) polyadenylation sequence.
- WPRE woodchuck posttranscriptional regulatory element
- BGH bovine growth hormone
- ChR2(L132C)-2A-EGFP (kind gift from Volker Busskampo - 2A self-cleaving peptide / CHYSEL 29 ) was constmcted by adapter PCR and subcloned into pAAV2-CAG-EGFP by replacement of EGFP using Clontech's in fusion kit.
- the viral vector (pAAV2-CAG- ChR2(L132C)-2A-EGFP-WPRE-bGH) was packaged (serotype 7) and affinity purified at the Gene Therapy Program of the University of Pennsylvania with a final infectious vims titer of 2.26x10 U genome copies / ml.
- Electrophysiological recordings from hippocampal neurons For whole-cell recordings in cultured hippocampal neurons, patch pipettes with resistances of 5-10 ⁇ were filled with 129 mM potassium gluconate, 10 mM HEPES, 10 mM KC1, 4 mM MgATP and 0.3 mM Na 3 GTP, titrated to pH 7.2. Tyrode's solution was employed as the extracellular solution (125 mM NaCl, 2 mM KC1, 2 mM CaCl 2 , 1 mM MgCl 2 , 30 mM glucose and 25 mM HEPES, titrated to pH 7.4).
- the nominally Ca ++ -free extracellular solution contained this same solution except that it had 0 mM Ca ++ and 3 mM Mg**. Recordings were conducted in the presence of the excitatory synaptic transmission blockers, l,2,3,4-tetrahydro-6-nitro- 2,3-dioxo-benzo[fJquinoxaline-7-sulfonamide (NBQX, 10 ⁇ , Sigma) and D(-)-2- Amino- 5-phosphonopentanoic acid (AP-5, 50 ⁇ , Sigma). For voltage-clamp recordings 1 ⁇ tetrodotoxin was added to the extracellular solution. To inhibit B -channel activity, 1 mM TEA was added.
- Electrophysiological signals were amplified using an Axopatch 200A amplifier (Axon Instruments, Union City, CA), filtered at 10 kHz, digitized with an Axon Digidata 1600 (50 Hz) and acquired and analyzed using pClamp 0 - software (Axon Instruments).
- CatCh-expressing neurons facilitates activation with wavelengths away from the peak sensitivity, as exemplified for green light (532 nm) in figure 4d. This may confer benefits in terms of more effective tissue recruitment with deeper-penetrating green light.
- CatCh serves as a membrane bound fast Ca ++ - source, by temporarily increasing the local intracellular surface Ca ++ concentration, thereby neutralizing the negative surface charges (Fig. 7).
- BK channels Ca ++ -activated large conductance potassium channels 20 to potently repolarize the cell to its original resting potential within milliseconds after each action potential.
- TAA potassium channel inhibitor tetraethylammonium
- CatCh a channelrhodopsin with an elevated Ca ++ -permeability
- pairs increased light-sensitivity with fast kinetics and thus outperforms the WT ChR2 and the published slow and fast mutants (for a comparison of the properties of different ChR2 variants see table 1).
- This cavity would be located in a hydrophobic patch as part of the conserved transmembrane helix three (TM3), only a helical turn apart from CI 28.
- TM3 conserved transmembrane helix three
- TM4 D156
- CatCh When delivered to hippocampal pyramidal cells, CatCh exhibited a ⁇ 70-fold increase in light-sensitivity compared to WT ChR2. Usually, such an increased light efficacy is accompanied by a strongly prolonged open channel life- time 2 ' 6 ' 13 . This is not the case for CatCh. The observed light sensitivity differs markedly from what has been observed for other channelrhodopsins up to now. As explained below, the secondary effects on neuronal excitability are induced by Ca ++ influx through CatCh.
- CatCh shows increased spike-reliability and precision during high-frequency light-stimulation, reducing extra spikes and eliminating artificial plateau potentials typically observed in WT-expressing cells at stimulation frequencies above 20 Hz 3 ' 7 ' 12 . 1 -ms light pulses delivered at room temperature induced reliable spike trains up to 50 Hz in CatCh-expressing pyramidal cells (their natural limit of natural spiking; Fig. 4f). Higher frequency CatCh-mediated spike induction on faster spiking cells such as cortical
- the continuous Ca ++ -influx during persistent illumination may activate calcium-activated non-selective cation channels, which further support the maintenance of a stationary depolarization level.
- a prerequisite for successful high-frequency pulsed stimulation is a fast repolarization of the cell following each action potential.
- the slightly increased life-time of the open state of CatCh compared to the WT should limit its maximal stimulation frequency.
- an enhanced Ca ++ -permeability counteracts this limitation by potent activation of large conductance calcium-gated potassium channels (B channels). This re- establishes the resting membrane potential of the neuron within milliseconds after each action potential. This theory was confirmed by the inhibition of BK channels with the open-channel blocker TEA, which resulted in a persistent depolarization of the neuron during the length of a pulse stimulation protocol.
- CatCh has an increased light- sensitivity similar to the slow-mutants or SFO's but with much accelerated response kinetics owing to its increased Ca ++ -permeability and the consequences on neuronal excitability. This makes CatCh superior to available ChR2 variants, where a high light sensitivity had to be established at cost of fast kinetics and vice versa with respect to the fast channelrhodopsins 7 ' 12 (for an overview see table 1).
- T on values from single turnover measurements, ⁇ : in 200 mM guanidine-HCl, RT, -60 mV I: HCN, -60 mV; I WT ⁇ WT ChR2 current under respective experimental conditions, J: light intensity required to induce action potential; EC50: apparent half-saturating light intensities, max spike v. maximal light-pulse induced reliable spike frequency, AD: artificial after depolarization, "data cannot be determined accurately and represents lower limit estimation, *extrapolated value, Subthreshold depolarization, rf two-color on/off control with blue- yellow
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11760432.2A EP2614079B1 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
ES11760432.2T ES2545992T3 (en) | 2010-09-08 | 2011-09-08 | Mutant Canalrodopsin 2 |
DK11760432.2T DK2614079T3 (en) | 2010-09-08 | 2011-09-08 | MUTANT CHANNEL RHODOPSIN 2 |
BR112013005634A BR112013005634A2 (en) | 2010-09-08 | 2011-09-08 | mutant channel-rhodopsin 2 |
JP2013527595A JP5933556B2 (en) | 2010-09-08 | 2011-09-08 | Mutant channel rhodopsin 2 |
CA2810757A CA2810757C (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
SI201130552T SI2614079T1 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
MX2013002591A MX347453B (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2. |
RU2013115454/10A RU2595384C2 (en) | 2010-09-08 | 2011-09-08 | Mutant channel rhodopsin-2 |
US13/821,353 US8748578B2 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
PL11760432T PL2614079T3 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
KR1020137008660A KR101945962B1 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
AU2011298745A AU2011298745B2 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
SG2013016332A SG188409A1 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
CN201180052156.9A CN103261219B (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
IL225060A IL225060A (en) | 2010-09-08 | 2013-03-05 | Mutant channelrhodopsin 2 |
HRP20150846TT HRP20150846T1 (en) | 2010-09-08 | 2015-08-10 | Mutant channelrhodopsin 2 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38079310P | 2010-09-08 | 2010-09-08 | |
EP10175832.4 | 2010-09-08 | ||
US61/380,793 | 2010-09-08 | ||
EP10175832 | 2010-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012032103A1 true WO2012032103A1 (en) | 2012-03-15 |
Family
ID=42979822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/065510 WO2012032103A1 (en) | 2010-09-08 | 2011-09-08 | Mutant channelrhodopsin 2 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8748578B2 (en) |
EP (1) | EP2614079B1 (en) |
JP (1) | JP5933556B2 (en) |
KR (1) | KR101945962B1 (en) |
CN (1) | CN103261219B (en) |
AU (1) | AU2011298745B2 (en) |
BR (1) | BR112013005634A2 (en) |
CA (1) | CA2810757C (en) |
DK (1) | DK2614079T3 (en) |
ES (1) | ES2545992T3 (en) |
HR (1) | HRP20150846T1 (en) |
HU (1) | HUE025952T2 (en) |
IL (1) | IL225060A (en) |
MX (1) | MX347453B (en) |
PL (1) | PL2614079T3 (en) |
PT (1) | PT2614079E (en) |
RU (1) | RU2595384C2 (en) |
SG (1) | SG188409A1 (en) |
SI (1) | SI2614079T1 (en) |
WO (1) | WO2012032103A1 (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2635111A2 (en) * | 2010-11-05 | 2013-09-11 | The Board of Trustees of The Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
WO2013134295A1 (en) * | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelrhodopsin-2 (chop2) mutations and methods of use |
US8962589B2 (en) | 2008-05-29 | 2015-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical control of secondary messengers |
US9079940B2 (en) | 2010-03-17 | 2015-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Light-sensitive ion-passing molecules |
US9084885B2 (en) | 2008-06-17 | 2015-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
US9101690B2 (en) | 2005-07-22 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
WO2015161308A1 (en) * | 2014-04-18 | 2015-10-22 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
US9175095B2 (en) | 2010-11-05 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
WO2015167639A1 (en) * | 2014-02-07 | 2015-11-05 | Massachusetts Institute Of Technology | Blue light-activated ion channel molecules and uses thereof |
US9187745B2 (en) | 2007-01-10 | 2015-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
US9249200B2 (en) | 2008-04-23 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Expression vector comprising a nucleotide sequence encoding a Volvox carteri light-activated ion channel protein (VChR1) and implantable device thereof |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US9271674B2 (en) | 2010-11-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US9284353B2 (en) | 2007-03-01 | 2016-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian codon optimized nucleotide sequence that encodes a variant opsin polypeptide derived from Natromonas pharaonis (NpHR) |
US9309296B2 (en) | 2008-11-14 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-based stimulation of target cells and modifications thereto |
US9365628B2 (en) | 2011-12-16 | 2016-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
CN105744830A (en) * | 2013-11-29 | 2016-07-06 | 堀雅敏 | Pest control method and control device |
US9421258B2 (en) | 2010-11-05 | 2016-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Optically controlled CNS dysfunction |
US9522288B2 (en) | 2010-11-05 | 2016-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light for use in optogenetic methods |
US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
US9693692B2 (en) | 2007-02-14 | 2017-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
US9730981B2 (en) | 2006-05-04 | 2017-08-15 | Salus University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
WO2017207745A1 (en) | 2016-06-03 | 2017-12-07 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Mutant light-inducible ion channel of channelrhodopsin |
WO2017207761A1 (en) | 2016-06-03 | 2017-12-07 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Mutant light-inducible ion channel of chrimson |
US9968689B2 (en) | 2010-05-04 | 2018-05-15 | Wayne State University | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
US9992981B2 (en) | 2010-11-05 | 2018-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US10086012B2 (en) | 2010-11-05 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of memory function |
US10220092B2 (en) | 2013-04-29 | 2019-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
US10307609B2 (en) | 2013-08-14 | 2019-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
US10426970B2 (en) | 2007-10-31 | 2019-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
US10569099B2 (en) | 2005-07-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US10568516B2 (en) | 2015-06-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
WO2020054868A1 (en) | 2018-09-14 | 2020-03-19 | 国立大学法人名古屋工業大学 | Photoresponsive protein and utilization thereof |
US10711242B2 (en) | 2008-06-17 | 2020-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
US10974064B2 (en) | 2013-03-15 | 2021-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
US11103723B2 (en) | 2012-02-21 | 2021-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating neurogenic disorders of the pelvic floor |
US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
EP4223768A1 (en) | 2022-02-04 | 2023-08-09 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Novel mutant bacteriorhodopsin-like-channelrhodopsin ion channel |
EP4119666A4 (en) * | 2020-03-13 | 2024-04-03 | Nagoya Inst Tech | Light-responsive protein for color recognition and use thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015142984A1 (en) * | 2014-03-18 | 2015-09-24 | Washington University | Methods and compositions for red-shifted chromophore substitution for optogenetic applications |
AU2017372351B2 (en) * | 2016-11-06 | 2019-12-12 | Nanoscope Technologies Llc | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
CA3059652A1 (en) * | 2017-04-12 | 2018-10-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | New optogenetic tool |
CN110483645B (en) * | 2018-05-14 | 2023-05-12 | 郑州大学第一附属医院 | Mitochondrial localization proton pump type rhodopsin, mutant protein thereof and application thereof |
US11313860B2 (en) | 2018-07-26 | 2022-04-26 | Council Of Scientific & Industrial Research | Screening kit for detection of grades of cervical cancer and process for the preparation thereof |
WO2022176754A1 (en) * | 2021-02-18 | 2022-08-25 | 国立大学法人名古屋工業大学 | Blue light- or indigo light-responsive proteins and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003084994A2 (en) | 2002-04-11 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of biological photoreceptors as directly light-activated ion channels |
EP2112510A1 (en) * | 2008-04-22 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of biological photo-receptors as direct light-controlled ion channels |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2112501A1 (en) | 1998-02-05 | 2009-10-28 | Novartis Ag | Method and device for measuring luminescence |
US8470790B2 (en) * | 2006-05-04 | 2013-06-25 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
NZ602416A (en) * | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
-
2011
- 2011-09-08 JP JP2013527595A patent/JP5933556B2/en active Active
- 2011-09-08 WO PCT/EP2011/065510 patent/WO2012032103A1/en active Application Filing
- 2011-09-08 DK DK11760432.2T patent/DK2614079T3/en active
- 2011-09-08 RU RU2013115454/10A patent/RU2595384C2/en active
- 2011-09-08 CA CA2810757A patent/CA2810757C/en active Active
- 2011-09-08 BR BR112013005634A patent/BR112013005634A2/en not_active Application Discontinuation
- 2011-09-08 ES ES11760432.2T patent/ES2545992T3/en active Active
- 2011-09-08 SI SI201130552T patent/SI2614079T1/en unknown
- 2011-09-08 CN CN201180052156.9A patent/CN103261219B/en active Active
- 2011-09-08 PL PL11760432T patent/PL2614079T3/en unknown
- 2011-09-08 AU AU2011298745A patent/AU2011298745B2/en active Active
- 2011-09-08 KR KR1020137008660A patent/KR101945962B1/en active IP Right Grant
- 2011-09-08 US US13/821,353 patent/US8748578B2/en active Active
- 2011-09-08 PT PT117604322T patent/PT2614079E/en unknown
- 2011-09-08 MX MX2013002591A patent/MX347453B/en active IP Right Grant
- 2011-09-08 EP EP11760432.2A patent/EP2614079B1/en active Active
- 2011-09-08 HU HUE11760432A patent/HUE025952T2/en unknown
- 2011-09-08 SG SG2013016332A patent/SG188409A1/en unknown
-
2013
- 2013-03-05 IL IL225060A patent/IL225060A/en active IP Right Grant
-
2015
- 2015-08-10 HR HRP20150846TT patent/HRP20150846T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003084994A2 (en) | 2002-04-11 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of biological photoreceptors as directly light-activated ion channels |
EP2112510A1 (en) * | 2008-04-22 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of biological photo-receptors as direct light-controlled ion channels |
Non-Patent Citations (31)
Title |
---|
A. BERNDT, BIOPHYSICAL JOURNA, vol. 96, no. 3, 3465, 1 February 2009 (2009-02-01), pages 671A, XP025921930, DOI: 10.1016/j.bpj.2008.12.3547 * |
ALLOCCA, M. ET AL.: "Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors", J VIROLOGY, vol. 81, 2007, pages 11372 - 11380, XP002528463, DOI: doi:10.1128/JVI.01327-07 |
BAMANN, C., GUETA, R., KLEINLOGEL, S., NAGEL, G., BAMBERG, E.: "Structural guidance of the photocycle of channelrhodopsin-2 by an interhelical hydrogen bond", BIOCHEMISTRY, vol. 49, 2010, pages 267 - 278, XP055195222, DOI: doi:10.1021/bi901634p |
BAMANN, C., KIRSCH, T., NAGEL, G., BAMBERG, E.: "Spectral characteristics of the photocycle of channelrhodopsin-2 and its implication for channel function", J MOL BIOL, vol. 375, 2008, pages 686 - 694, XP022400110, DOI: doi:10.1016/j.jmb.2007.10.072 |
BERNDT, A., YIZHAR, O., GUNAYDIN, L., HEGEMANN, P., DEISSEROTH, K.: "Bi-stable neural state switches", NAT NEUROSCI, vol. 12, 2009, pages 229 - 234, XP055106451, DOI: doi:10.1038/nn.2247 |
BI, A. ET AL.: "Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration", NEURON, vol. 50, 2006, pages 23 - 33, XP002406402, DOI: doi:10.1016/j.neuron.2006.02.026 |
BOYDEN, E., ZHANG, F., BAMBERG, E., NAGEL, G., DEISSEROTH, K.: "Millisecond- timescale, genetically targeted optical control of neural activity", NAT NEUROSCI, vol. 8, 2005, pages 1263 - 1268, XP055012811, DOI: doi:10.1038/nn1525 |
BUSSKAMP, V. ET AL.: "Genetic reactivation of cone photoreceptors restores visual responses in retinitis piglnentosa", SCIENCE, vol. 329, 2010, pages 413 - 417, XP002679057, DOI: doi:10.1126/SCIENCE.1190897 |
CALDWELL, J. ET AL.: "Increases in intracellular calcium triggered by channelrhodopsin-2 potentiate the response of metabotropic glutamate receptor mGluR7", J BIOL CHEMISTRY, vol. 283, 2008 |
DE FELIPE, P. ET AL.: "E unum pluribus: multiple proteins from a self-processing polyprotein", TRENDS BIOTECHNOL, vol. 24, 2006, pages 68 - 75, XP025052212, DOI: doi:10.1016/j.tibtech.2005.12.006 |
ELLIS-DAVIES, G. C. R.: "Neurobiology with caged calcium", CHEM REV, vol. 108, 2008, pages 1603 - 1613 |
FABER, E., SAH, P.: "Calcium-activateed potassium-channels: multiple contributions to neuronal function", NEUROSCIENTIST, vol. 9, 2003, pages 181 - 194 |
FELDBAUER, K. ET AL.: "Channelrhodopsin-2 is a leaky proton pump", PROC NATL ACAD SCI USA, 2009 |
FRANKENHAUSER, B., HODGKIN, A.: "The action of calcium on the electrical properties of squid axons", JPHYSIOL (LOND, vol. 137, 1957, pages 218 - 244 |
GUNAYDIN, L. ET AL.: "Ultrafast optogenetic control", NAT NEUROSCI, vol. 13, 2010, pages 387 - 392, XP055135011, DOI: doi:10.1038/nn.2495 |
HILLE, B., WOODHULL, B., SHAPIRO, B.: "Negative surface charge near sodium channels of nerve: divalent ions, monovalent ions, and pH", PHILOS TRANS R SOC LOND B BIOL SCI, vol. 270, 1975, pages 301 - 318 |
HUMPHREY, W., DALKE, A., SCHULTEN, K.: "VMD - Visual Molecular Dynamics", J MOLEC GRAPHICS, vol. 14, 1996, pages 33 - 38, XP055140690, DOI: doi:10.1016/0263-7855(96)00018-5 |
JOH, N., OBERAI, A., YANG, D., WHITE1EGGE, J., BOWIE, J.: "Similar energetic contributions of packing in the core of membrane and water-soluble proteins", JAM CHEM SOC, vol. 131, 2009, pages 10846 - 10847 |
KLEINLOGEL S. ET AL: "ULTRA LIGHT SENSITIVE AND FAST NEURONAL ACTIVATION WITH THE CA2+PERMEABLE CHANNELRHODOPSIN CATCH", NATURE NEUROSCIENCE, vol. 14, no. 4, 1 April 2011 (2011-04-01), pages 513 - 520, XP002661265 * |
LAGALI, P. ET AL.: "Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration", NAT NEUROSCI, vol. 11, 2008, pages 667 - 675, XP055073427, DOI: doi:10.1038/nn.2117 |
LIN, J., LIN, M., STEINBACH, P., TSIEN, R.: "Characterization of engineered channelrhodopsin variants with improved properties and kinetics", BIOPHYS J, vol. 96, 2009, pages 1803 - 1814, XP008151895, DOI: doi:10.1016/j.bpj.2008.11.034 |
LORENZ, C., PUSCH, M., JENTSCH, T.: "Heteromultimeric C1C chloride channels with novel properties", PROC NATL ACAD SCI USA, vol. 92, 1996, pages 13362 - 13366 |
MULLER, R., FINKELSTEIN, A.: "The effect of surface charge on the voltage-dependent conductance induced in thin lipid membranes by monazomycin", J GENERAL PHYSIOL, vol. 60, 1972, pages 285 - 306 |
NACK, M. ET AL.: "The DC gate in Channelrhodopsin-2: crucial hydrogen bonding interaction between C128 and D156", PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, vol. 9, 2010, pages 194 - 198 |
NAGEL, G. ET AL.: "Channelrhodopsin-2, a directly light-gated cation-selective membrane channel", PROC NATL ACAD SCI USA, vol. 100, 2003, pages 13940 - 13945, XP002406405, DOI: doi:10.1073/pnas.1936192100 |
NAGEL, G. ET AL.: "Light activation of channelrhodopsin-2 in excitable cells of Caenorhabditis elegans triggers rapid behavioral responses", CURR BIOL, vol. 15, 2005, pages 2279 - 2284, XP027513347, DOI: doi:10.1016/j.cub.2005.11.032 |
SUBRAMANIAM, S., FARUQI, A., OESTERHELT, D., HENDERSON, R.: "Electron diffraction studies of light-induced conformational changes in the Leu-93?Ala bacteriorhodopsin mutant", PROC NAT ACAD SCI USA, vol. 94, 1997, pages 1767 - 1772 |
SUBRAMANIAM, S., GREENHALGH, D., RATH, P., ROTHSCHILD, K., KHORANA, H.: "Replacement of leucine-93 by alanine or threonine slows down the decay of the N and O intermediates in the photocycle of bacteriorhodopsin: implications for proton uptake and 13-cis-retinal all-trans-retinal reisomerization", PROC NATL ACAD SCI USA, vol. 88, 1991, pages 6873 - 6877 |
THYAGARAJAN, S. ET AL.: "Visual function in mice with photoreceptor degeneration and transgenic expression of channelrhodopsin 2 in ganglion cells", JNEUROSCI, vol. 30, 2010, pages 8745 - 8758 |
WEBER, W.-M.: "Ion currents in Xenopus laevis oocytes: state of the art", BIOCHIM BIOPHYS ACTA, vol. 1421, 1999, pages 213 - 233, XP004273061, DOI: doi:10.1016/S0005-2736(99)00135-2 |
ZHANG, F. ET AL.: "Multimodal fast optical interrogation of neural circuitry", NATURE, vol. 446, 2007, pages 633 - 639, XP002487911, DOI: doi:10.1038/nature05744 |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10094840B2 (en) | 2005-07-22 | 2018-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US10627410B2 (en) | 2005-07-22 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US10046174B2 (en) | 2005-07-22 | 2018-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | System for electrically stimulating target neuronal cells of a living animal in vivo |
US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US9829492B2 (en) | 2005-07-22 | 2017-11-28 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable prosthetic device comprising a cell expressing a channelrhodopsin |
US10569099B2 (en) | 2005-07-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US10036758B2 (en) | 2005-07-22 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Delivery of a light-activated cation channel into the brain of a subject |
US9101690B2 (en) | 2005-07-22 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US10422803B2 (en) | 2005-07-22 | 2019-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US9360472B2 (en) | 2005-07-22 | 2016-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical-based screening of ion-channel modulators |
US10451608B2 (en) | 2005-07-22 | 2019-10-22 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical-based screening of ion-channel modulators |
US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
US9278159B2 (en) | 2005-07-22 | 2016-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US9730981B2 (en) | 2006-05-04 | 2017-08-15 | Salus University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
US10105551B2 (en) | 2007-01-10 | 2018-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US11007374B2 (en) | 2007-01-10 | 2021-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US9187745B2 (en) | 2007-01-10 | 2015-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US10369378B2 (en) | 2007-01-10 | 2019-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US9693692B2 (en) | 2007-02-14 | 2017-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
US10589123B2 (en) | 2007-03-01 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
US9757587B2 (en) | 2007-03-01 | 2017-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic method for generating an inhibitory current in a mammalian neuron |
US9284353B2 (en) | 2007-03-01 | 2016-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian codon optimized nucleotide sequence that encodes a variant opsin polypeptide derived from Natromonas pharaonis (NpHR) |
US9855442B2 (en) | 2007-03-01 | 2018-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Method for optically controlling a neuron with a mammalian codon optimized nucleotide sequence that encodes a variant opsin polypeptide derived from natromonas pharaonis (NpHR) |
US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
US10426970B2 (en) | 2007-10-31 | 2019-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
US9878176B2 (en) | 2008-04-23 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | System utilizing Volvox carteri light-activated ion channel protein (VChR1) for optical stimulation of target cells |
US9394347B2 (en) | 2008-04-23 | 2016-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating parkinson's disease by optically stimulating target cells |
US10350430B2 (en) | 2008-04-23 | 2019-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | System comprising a nucleotide sequence encoding a volvox carteri light-activated ion channel protein (VCHR1) |
US9249200B2 (en) | 2008-04-23 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Expression vector comprising a nucleotide sequence encoding a Volvox carteri light-activated ion channel protein (VChR1) and implantable device thereof |
US9453215B2 (en) | 2008-05-29 | 2016-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical control of secondary messengers |
US8962589B2 (en) | 2008-05-29 | 2015-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical control of secondary messengers |
US10711242B2 (en) | 2008-06-17 | 2020-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
US9084885B2 (en) | 2008-06-17 | 2015-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
US10583309B2 (en) | 2008-07-08 | 2020-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
US9308392B2 (en) | 2008-07-08 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
US10071132B2 (en) | 2008-11-14 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-based stimulation of target cells and modifications thereto |
US10064912B2 (en) | 2008-11-14 | 2018-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-based stimulation of target cells and modifications thereto |
US9458208B2 (en) | 2008-11-14 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-based stimulation of target cells and modifications thereto |
US9309296B2 (en) | 2008-11-14 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-based stimulation of target cells and modifications thereto |
US9079940B2 (en) | 2010-03-17 | 2015-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Light-sensitive ion-passing molecules |
US9604073B2 (en) | 2010-03-17 | 2017-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Light-sensitive ion-passing molecules |
US9249234B2 (en) | 2010-03-17 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Light-sensitive ion-passing molecules |
US9359449B2 (en) | 2010-03-17 | 2016-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Light-sensitive ion-passing molecules |
US9968689B2 (en) | 2010-05-04 | 2018-05-15 | Wayne State University | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
US9968652B2 (en) | 2010-11-05 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-controlled CNS dysfunction |
US10196431B2 (en) | 2010-11-05 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
US9992981B2 (en) | 2010-11-05 | 2018-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
EP2635111A2 (en) * | 2010-11-05 | 2013-09-11 | The Board of Trustees of The Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
EP2635111A4 (en) * | 2010-11-05 | 2014-10-15 | Univ Leland Stanford Junior | Stabilized step function opsin proteins and methods of using the same |
US9850290B2 (en) | 2010-11-05 | 2017-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
US9175095B2 (en) | 2010-11-05 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
US10568307B2 (en) | 2010-11-05 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
US9340589B2 (en) | 2010-11-05 | 2016-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
US9421258B2 (en) | 2010-11-05 | 2016-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Optically controlled CNS dysfunction |
US10086012B2 (en) | 2010-11-05 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of memory function |
US9522288B2 (en) | 2010-11-05 | 2016-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light for use in optogenetic methods |
US10252076B2 (en) | 2010-11-05 | 2019-04-09 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light for use in optogenetic methods |
US10914803B2 (en) | 2010-11-22 | 2021-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US10018695B2 (en) | 2010-11-22 | 2018-07-10 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US9615789B2 (en) | 2010-11-22 | 2017-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US9271674B2 (en) | 2010-11-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US10371776B2 (en) | 2010-11-22 | 2019-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US9365628B2 (en) | 2011-12-16 | 2016-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
US9840541B2 (en) | 2011-12-16 | 2017-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
US10087223B2 (en) | 2011-12-16 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
US9505817B2 (en) | 2011-12-16 | 2016-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
US9969783B2 (en) | 2011-12-16 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
US10538560B2 (en) | 2011-12-16 | 2020-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
US11103723B2 (en) | 2012-02-21 | 2021-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating neurogenic disorders of the pelvic floor |
WO2013134295A1 (en) * | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelrhodopsin-2 (chop2) mutations and methods of use |
AU2019216638B2 (en) * | 2012-03-05 | 2021-07-08 | Wayne State University | Identification of Channelopsin-2 (Chop2) mutations and methods of use |
AU2017239601B2 (en) * | 2012-03-05 | 2019-05-16 | Wayne State University | Identification of Channelopsin-2 (Chop2) mutations and methods of use |
US10947281B2 (en) | 2012-03-05 | 2021-03-16 | Wayne State University | Identification of channelrhodopsin-2 (ChR2) mutations and methods of use |
US10974064B2 (en) | 2013-03-15 | 2021-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
US10220092B2 (en) | 2013-04-29 | 2019-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
US10307609B2 (en) | 2013-08-14 | 2019-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
CN105744830A (en) * | 2013-11-29 | 2016-07-06 | 堀雅敏 | Pest control method and control device |
EP3075245A4 (en) * | 2013-11-29 | 2017-08-23 | Hori Masatoshi | Pest control method and control device |
US11064689B2 (en) | 2013-11-29 | 2021-07-20 | Shin-Etsu Handotai Co., Ltd. | Pest control method and control device |
WO2015167639A1 (en) * | 2014-02-07 | 2015-11-05 | Massachusetts Institute Of Technology | Blue light-activated ion channel molecules and uses thereof |
US10392426B2 (en) | 2014-02-07 | 2019-08-27 | Massachusetts Institute Of Technology | Blue-light-activated ion channel polypeptides and uses thereof |
WO2015161308A1 (en) * | 2014-04-18 | 2015-10-22 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
US10590181B2 (en) | 2014-04-18 | 2020-03-17 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
US10568516B2 (en) | 2015-06-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
WO2017207745A1 (en) | 2016-06-03 | 2017-12-07 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Mutant light-inducible ion channel of channelrhodopsin |
WO2017207761A1 (en) | 2016-06-03 | 2017-12-07 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Mutant light-inducible ion channel of chrimson |
JP2019522469A (en) * | 2016-06-03 | 2019-08-15 | マックス−プランク−ゲゼルシャフト ツア フェルデルンク デア ヴィッセンシャフテン エー.ファウ. | Mutant light-induced ion channel of channel rhodopsin |
US11384132B2 (en) | 2016-06-03 | 2022-07-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Mutant light-inducible ion channel of chrimson |
US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
CN112689675A (en) * | 2018-09-14 | 2021-04-20 | 国立大学法人名古屋工业大学 | Light-responsive protein and application thereof |
WO2020054868A1 (en) | 2018-09-14 | 2020-03-19 | 国立大学法人名古屋工業大学 | Photoresponsive protein and utilization thereof |
JPWO2020054868A1 (en) * | 2018-09-14 | 2021-08-30 | 国立大学法人 名古屋工業大学 | Photoresponsive proteins and their uses |
CN112689675B (en) * | 2018-09-14 | 2023-09-19 | 国立大学法人名古屋工业大学 | Light responsive protein and application thereof |
EP4119666A4 (en) * | 2020-03-13 | 2024-04-03 | Nagoya Inst Tech | Light-responsive protein for color recognition and use thereof |
EP4223768A1 (en) | 2022-02-04 | 2023-08-09 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Novel mutant bacteriorhodopsin-like-channelrhodopsin ion channel |
Also Published As
Publication number | Publication date |
---|---|
RU2013115454A (en) | 2014-10-20 |
CN103261219B (en) | 2017-05-17 |
CA2810757C (en) | 2020-06-09 |
MX347453B (en) | 2017-04-27 |
HRP20150846T1 (en) | 2015-09-11 |
HUE025952T2 (en) | 2016-04-28 |
AU2011298745A1 (en) | 2013-03-21 |
US8748578B2 (en) | 2014-06-10 |
PL2614079T3 (en) | 2016-01-29 |
RU2595384C2 (en) | 2016-08-27 |
BR112013005634A2 (en) | 2017-06-27 |
MX2013002591A (en) | 2013-07-22 |
EP2614079A1 (en) | 2013-07-17 |
KR101945962B1 (en) | 2019-02-08 |
CA2810757A1 (en) | 2012-03-15 |
EP2614079B1 (en) | 2015-07-15 |
KR20130108335A (en) | 2013-10-02 |
US20130281379A1 (en) | 2013-10-24 |
JP2013544494A (en) | 2013-12-19 |
DK2614079T3 (en) | 2015-08-10 |
SG188409A1 (en) | 2013-04-30 |
SI2614079T1 (en) | 2015-10-30 |
AU2011298745B2 (en) | 2015-05-07 |
CN103261219A (en) | 2013-08-21 |
PT2614079E (en) | 2015-10-06 |
IL225060A (en) | 2016-10-31 |
ES2545992T3 (en) | 2015-09-17 |
JP5933556B2 (en) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8748578B2 (en) | Mutant channelrhodopsin 2 | |
Kleinlogel et al. | Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatCh | |
US7144733B2 (en) | Bio-synthetic photostimulators and methods of use | |
US8309350B2 (en) | Photoreactive regulator of protein function and methods of use thereof | |
US20120214188A1 (en) | Light-activated ion channel molecules and uses thereof | |
WO2015167639A1 (en) | Blue light-activated ion channel molecules and uses thereof | |
US11384132B2 (en) | Mutant light-inducible ion channel of chrimson | |
US20190218256A1 (en) | Mutant light-inducible ion channel of channelrhodopsin | |
JP2020516295A (en) | New optogenetics tool | |
Meijer | Genetically encoded optical control of protein function | |
Li | G-Protein Modulation of Ion Channels and Control of Neuronal Excitability by Light | |
Chuong | Development of next-generation optical neural silencers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11760432 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 225060 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/002591 Country of ref document: MX Ref document number: 2011760432 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013527595 Country of ref document: JP Kind code of ref document: A Ref document number: 2810757 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011298745 Country of ref document: AU Date of ref document: 20110908 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20137008660 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013115454 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13821353 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013005634 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013005634 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130308 |